Rigel Pharmaceuticals

Company RIGL

Last mentioned: Mar 5, 2026

Stories mentioning Rigel Pharmaceuticals 2

pharma Neutral

Rigel and Cumberland Q4 Results Signal Commercial Maturity in Specialty Pharma

Rigel Pharmaceuticals and Cumberland Pharmaceuticals reported Q4 results that emphasize commercial execution and a shift toward sustainable profitability. Both companies are leveraging core hospital and oncology assets to navigate a market that increasingly rewards revenue-generating biotechs over speculative R&D.

2 sources
pharma Neutral

Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.

2 sources